DE60141773D1 - Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren - Google Patents

Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren

Info

Publication number
DE60141773D1
DE60141773D1 DE60141773T DE60141773T DE60141773D1 DE 60141773 D1 DE60141773 D1 DE 60141773D1 DE 60141773 T DE60141773 T DE 60141773T DE 60141773 T DE60141773 T DE 60141773T DE 60141773 D1 DE60141773 D1 DE 60141773D1
Authority
DE
Germany
Prior art keywords
ligands
use process
similar receptor
great
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60141773T
Other languages
English (en)
Inventor
Alan Aderem
Fumitaka Hayashi
David M Underhill
Adrian Ozinsky
Kelly D Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Systems Biology
Original Assignee
Institute for Systems Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23094403&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60141773(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Institute for Systems Biology filed Critical Institute for Systems Biology
Application granted granted Critical
Publication of DE60141773D1 publication Critical patent/DE60141773D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60141773T 2001-04-20 2001-07-20 Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren Expired - Lifetime DE60141773D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28547701P 2001-04-20 2001-04-20
PCT/US2001/022978 WO2002085933A1 (en) 2001-04-20 2001-07-20 Toll-like receptor 5 ligands and methods of use

Publications (1)

Publication Number Publication Date
DE60141773D1 true DE60141773D1 (de) 2010-05-20

Family

ID=23094403

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60141773T Expired - Lifetime DE60141773D1 (de) 2001-04-20 2001-07-20 Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren

Country Status (5)

Country Link
US (3) US7915381B2 (de)
EP (1) EP1379552B2 (de)
AT (1) ATE463505T1 (de)
DE (1) DE60141773D1 (de)
WO (1) WO2002085933A1 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
WO2002085933A1 (en) 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
JP2006503825A (ja) * 2002-09-03 2006-02-02 フォンダシオン ユーロバク アジュバント
US7485432B2 (en) * 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
WO2004094671A2 (en) * 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Methods and products for identification and assessment of tlr ligands
WO2004096144A2 (en) * 2003-04-28 2004-11-11 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
JP2007502293A (ja) * 2003-08-12 2007-02-08 スリーエム イノベイティブ プロパティズ カンパニー ヒドロキシルアミン置換イミダゾ含有化合物
RU2006105101A (ru) * 2003-08-27 2007-10-10 3М Инновейтив Пропертиз Компани (US) Арилокси и арилалкиленокси замещенные имидазохинолины
CA2537763A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
AU2004278014B2 (en) * 2003-10-03 2011-04-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
WO2005040208A2 (en) * 2003-10-21 2005-05-06 Androclus Therapeutics, Soa Peptides derived from heat shock proteins binding toll-like receptors 2 and 4 and their use
US8173140B2 (en) 2003-10-22 2012-05-08 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
JP2007511527A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー オキシム置換イミダゾ環化合物
US8598192B2 (en) * 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
WO2005051317A2 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2005066170A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
CA2551399A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
KR20050073865A (ko) * 2004-01-12 2005-07-18 대한민국(전남대학교총장) 비브리오 패혈증균 편모 구성인자 플라젤린을유효성분으로 함유하는 백신 보조제
US8697873B2 (en) * 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005107381A2 (en) * 2004-05-07 2005-11-17 Hans-Gustaf Ljunggren Use of flagellin as an adjuvant for vaccine
DE102004024674A1 (de) * 2004-05-18 2005-12-15 Wolfgang Lorenz Mittel und Verfahren zur Diagnose, Prophylaxe und Therapie von Bindegewebserkrankungen
US8017779B2 (en) * 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US20070259881A1 (en) * 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
US7897609B2 (en) * 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8026366B2 (en) * 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7915281B2 (en) * 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US20090137390A1 (en) * 2004-06-30 2009-05-28 Eric Wendell Triplett Materials and methods for enhancing nitrogen fixation in plants
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
US7404963B2 (en) * 2004-10-01 2008-07-29 The University Of South Florida Flagellin-based adjuvants and vaccines
EP1819364A4 (de) * 2004-12-08 2010-12-29 3M Innovative Properties Co Immunmodulatorische zusammensetzungen, kombinationen und verfahren
WO2006066214A2 (en) * 2004-12-16 2006-06-22 Wake Forest University Health Sciences Use of flagellin in the immunotherapy of yersinia pestis
WO2006069198A1 (en) * 2004-12-22 2006-06-29 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
HU227285B1 (en) * 2004-12-29 2011-01-28 Mta Enzimologiai Intezet Modified flagellins and flagellar filaments useful as receptors and processes for producing same
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
JP5543068B2 (ja) * 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
JP2008527009A (ja) 2005-01-19 2008-07-24 バクシネート コーポレーション 病原体関連分子パターンおよび抗原を含む組成物ならびに免疫応答を刺激するためのそれらの使用
JP2008530022A (ja) * 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
JPWO2006085411A1 (ja) * 2005-02-10 2008-06-26 国立大学法人 北海道大学 免疫応答を惹起するための新規アジュバントおよびその利用
AU2006213746A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
US7700728B2 (en) * 2005-03-24 2010-04-20 Schering Corporation Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
WO2006107853A2 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
DE102005020798A1 (de) * 2005-04-28 2006-11-02 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verwendung von TLR- und/oder Nod2-Liganden zur Herstellung eines Arzneimittels zur Behandlung einer Krankheit des zentralen Nervensystems
KR100804507B1 (ko) 2005-05-17 2008-02-20 전남대학교산학협력단 플라젤린을 포함하는 천식 및 알레르기 질환 면역치료제
US8137930B2 (en) * 2005-10-28 2012-03-20 University Of Maryland, Baltimore Attenuated Salmonella enterica serovar paratyphi A and uses thereof
WO2007062043A1 (en) * 2005-11-23 2007-05-31 Coley Pharmaceutical Group Inc. Method of activating murine toll-like receptor 8
US8889149B2 (en) * 2006-02-16 2014-11-18 Wayne State University Use of flagellin to prevent and treat gram negative bacterial infection
AU2007224034B2 (en) 2006-03-07 2012-03-29 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2008008432A2 (en) * 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
US20100159486A1 (en) * 2006-11-01 2010-06-24 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
EP2121734B1 (de) * 2007-02-09 2013-05-08 Industry Foundation of Chonam National University Modifiziertes flagellin mit verbesserter stimulierung des toll-like-rezeptors 5
US20100330190A1 (en) * 2007-12-17 2010-12-30 Compans Richard W Immunogenic compositions and methods of use thereof
WO2009082440A2 (en) * 2007-12-18 2009-07-02 Vaxinnate Corporation Compositions of toll-like receptor agonists and malaria antigens and methods of use
WO2009128949A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of dengue viral proteins and methods of use
CN102170911B (zh) 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
CA2739454C (en) * 2008-10-03 2018-05-01 Emory University Methods for the treatment of graft-versus-host disease
WO2010080007A2 (ko) * 2009-01-09 2010-07-15 부산대학교 산학협력단 Ｔｏｌｌ 유사수용체２ 리간드로서 기능하는 그람양성균 유래의 리포단백질
US9096659B2 (en) 2009-03-18 2015-08-04 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against Pseudomonas aeruginosa
EP2432501B1 (de) * 2009-05-22 2016-12-14 The Institute for Systems Biology Sekretionsbezogene bakterielle proteine zur nlrc4-stimulation
US20120135037A1 (en) 2009-06-01 2012-05-31 Mizel Steven B Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
US20120171239A1 (en) 2009-09-03 2012-07-05 Mizel Steven B Immunogenic Conjugates for Producing Immune Responses to Drugs of Abuse and Methods of Use
ES2769326T3 (es) 2010-02-05 2020-06-25 Univ Cornell Métodos y composiciones para la inmunoterapia contra el cáncer usando células tumorales que expresan la proteína de fusión de flagelina y antígeno asociado al tumor
GB2481267B (en) 2010-06-15 2016-04-20 Univ Leicester Assay for determining the risk of a toll-like receptor containing foodstuff for causing systemic inflammation in vivo
JP5746761B2 (ja) 2010-06-25 2015-07-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 気道感染症の処置のための方法及び医薬組成物
US9872895B2 (en) 2010-09-24 2018-01-23 Emory University TLR5 ligands, therapeutic methods, and compositions related thereto
SG191830A1 (en) 2011-01-10 2013-08-30 Cleveland Biolabs Inc Use of toll-like receptor agonist for treating cancer
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
EP2847215A1 (de) * 2012-05-07 2015-03-18 Synthes GmbH Verfahren und vorrichtungen zur behandlung einer bandscheibenerkrankung
US9296792B2 (en) 2012-05-23 2016-03-29 The Board Of Trustees Of The Leland Stanford Junior University Ordered flagellin array as an immunostimulant
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
GB201306536D0 (en) * 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2015011254A1 (en) 2013-07-26 2015-01-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
MX2017001279A (es) 2014-07-30 2017-08-07 Cleveland Biolabs Inc Usos y composiciones de la flagelina.
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
NO3065748T3 (de) 2014-12-23 2018-04-21
SI3193901T1 (en) 2014-12-23 2018-06-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
HUE044617T2 (hu) 2015-06-15 2019-11-28 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
ME03563B (de) 2015-06-15 2020-07-20 4D Pharma Res Ltd Zusammensetzungen mit bakterienstämmen
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SG10201912324XA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MD3209310T2 (ro) 2015-11-20 2018-06-30 4D Pharma Res Ltd Compoziții care conțin tulpini bacteriene
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
CN114712405A (zh) 2016-03-04 2022-07-08 4D制药有限公司 包含细菌菌株的组合物
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
EP3630137B1 (de) 2017-05-22 2023-05-17 4D Pharma Research Limited Zusammensetzungen mit bakterienstämmen
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SI3638271T1 (sl) 2017-06-14 2021-01-29 4D Pharma Research Limited Sestavki, ki vsebujejo bakterijske seve
PL3600364T3 (pl) 2017-06-14 2021-01-11 4D Pharma Research Limited Kompozycje zawierające szczep bakteryjny z rodzaju megasphaera i ich zastosowania
CN111328287A (zh) 2017-07-04 2020-06-23 库瑞瓦格股份公司 新型核酸分子
AU2018304469B2 (en) 2017-07-20 2023-04-06 Spogen Biotech Inc. Bioactive polypeptides for improvements in plant protection, growth and productivity
KR102524577B1 (ko) * 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도
FR3114970B1 (fr) 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
WO2023275292A2 (en) 2021-06-30 2023-01-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosol composition for pulmonary delivery of flagellin
WO2024035137A1 (ko) * 2022-08-10 2024-02-15 주식회사 메디스팬 바실러스 서브틸리스 플라젤린 변이체 및 이의 용도
KR20240055629A (ko) * 2022-10-19 2024-04-29 전남대학교산학협력단 Tlr5 활성능을 가진 플라젤린 면역증강제 유도체의 진핵세포 발현시스템을 이용한 제조 및 응용

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5612035A (en) 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5614192A (en) 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US5618533A (en) 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
US5420109A (en) 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US5888810A (en) 1993-11-12 1999-03-30 The United States Of America As Represented By The Secretary Of Agriculture Campylobacteri jejuni flagellin-escherichia coli LT-B fusion protein
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
AU4070097A (en) * 1996-08-16 1998-03-06 Uab Research Foundation, The Mucosal immunogens for novel vaccines
US6797813B2 (en) * 1996-09-23 2004-09-28 Schering Corporation AK155 antibodies and binding fragments thereof
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
DE69932733T2 (de) * 1998-10-16 2007-08-16 The General Hospital Corp., Boston Photosensitizer-konjugate zur zielrichtung von intrazellulare pathogene
JP4623342B2 (ja) * 1999-05-25 2011-02-02 イミュネックス・コーポレーション Ｉｌ−１エータのｄｎａ及びポリペプチド
US6740487B1 (en) * 1999-06-10 2004-05-25 University Of Iowa Research Foundation Variant TLR4 nucleic acid and uses thereof
EP1290160B1 (de) * 2000-04-28 2006-03-29 Immunex Corporation Humanische pellino-polypeptide
FR2812304B1 (fr) * 2000-07-31 2004-12-17 Bio Merieux Complexe de lipo-viro-particules, procede de preparation et applications
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
WO2002009748A1 (en) * 2000-07-31 2002-02-07 Yale University Innate immune system-directed vaccines
WO2002085933A1 (en) 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use

Also Published As

Publication number Publication date
EP1379552B2 (de) 2014-11-19
WO2002085933A1 (en) 2002-10-31
ATE463505T1 (de) 2010-04-15
EP1379552A1 (de) 2004-01-14
US20120269855A1 (en) 2012-10-25
US20030044429A1 (en) 2003-03-06
US9085616B2 (en) 2015-07-21
EP1379552B1 (de) 2010-04-07
US20110008318A1 (en) 2011-01-13
US7915381B2 (en) 2011-03-29

Similar Documents

Publication Publication Date Title
DE60141773D1 (de) Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
MY125202A (en) Vaccine
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
ATE357930T1 (de) Immunmodulierende zusammensetzungen die eine an antigen gebundene immunstimulierende sequenz enthalten und deren verwendungen
WO2005037190A3 (en) Multiplex vaccines
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
EP1594536A4 (de) Adjuvante influenza-vakzine
TR200103574T2 (tr) Amid ikameli/katkılı imidazokinolinler
WO2004030608A3 (en) Nanoemulsion vaccines
NO20063254L (no) Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
ATE315405T1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
MXPA05014016A (es) Proteinas portadoras para vacunas.
BR0210225A (pt) Holotoxina do cólera imunogênica mutante, composição imunogênica, método para realçar a resposta imune de um hospedeiro vertebrado a um antìgeno, sequência de dna isolada e purificada, molécula de ácido nucleico, célula hospedeira, método para produzir uma holotoxina do cólera imunogênica mutante, e, uso de uma holotoxina do cólera mutante
MX343752B (es) Antigenos de neisseria meningitidis y composiciones que los contienen.
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
SG157951A1 (en) Cripto blocking antibodies and uses thereof
CY1108387T1 (el) Ανταγωνιστες ανασυνδυασμενης il-18 χρησιμοι στη θεραπεια παθησεων που εμφανιζονται με διαμεσολαβηση της il-18
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
IL154913A0 (en) Composition comprising immunogenic microparticles
DK1353689T3 (da) Immuniseringspræparater og anvendelse deraf
SG167667A1 (en) Nucleic acid compositions for stimulating immune responses
WO2003025119A3 (en) Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine

Legal Events

Date Code Title Description
8363 Opposition against the patent